MCID: BCT006
MIFTS: 31

Bacterial Conjunctivitis

Categories: Eye diseases, Immune diseases

Aliases & Classifications for Bacterial Conjunctivitis

MalaCards integrated aliases for Bacterial Conjunctivitis:

Name: Bacterial Conjunctivitis 12 15 73
Conjunctivitis, Bacterial 44
Purulent Conjunctivitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9700
ICD10 33 H10.0
MeSH 44 D003234
NCIt 50 C53656
SNOMED-CT 68 17482009
UMLS 73 C0009768

Summaries for Bacterial Conjunctivitis

MalaCards based summary : Bacterial Conjunctivitis, also known as conjunctivitis, bacterial, is related to conjunctivitis and purpura fulminans. An important gene associated with Bacterial Conjunctivitis is GCNT2 (Glucosaminyl (N-Acetyl) Transferase 2 (I Blood Group)). The drugs Moxifloxacin and Polyestradiol phosphate have been mentioned in the context of this disorder. Affiliated tissues include eye and testes, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Bacterial Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis

Diseases related to Bacterial Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
# Related Disease Score Top Affiliating Genes
1 conjunctivitis 11.6
2 purpura fulminans 9.9
3 purpura 9.9
4 iridocyclitis 9.9
5 degenerative myopia 9.9 CRYAA GCNT2
6 ophthalmia neonatorum 9.8 GCNT2 MTR
7 cataract 44 9.8 CRYAA GCNT2
8 ophthalmomyiasis 9.8
9 trachoma 9.8
10 blepharoconjunctivitis 9.8
11 haemophilus influenzae 9.8
12 acute conjunctivitis 9.8
13 blepharitis 9.8

Graphical network of the top 20 diseases related to Bacterial Conjunctivitis:



Diseases related to Bacterial Conjunctivitis

Symptoms & Phenotypes for Bacterial Conjunctivitis

GenomeRNAi Phenotypes related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.47 GCNT2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 9.47 GCNT2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.47 CRYAA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.47 CRYAA
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.47 GCNT2
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.47 CRYAA GCNT2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.47 CRYAA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.47 GCNT2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.47 CRYAA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.47 GCNT2
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.47 GCNT2
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.47 GCNT2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.47 CRYAA

Drugs & Therapeutics for Bacterial Conjunctivitis

Drugs for Bacterial Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
2
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2 28014-46-2
3
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2 35189-28-7 6540478
4 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 979-32-8
5
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
6
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
7
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
8 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Antibiotics, Antitubercular Phase 4,Phase 3
11 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Contraceptives, Oral Phase 4,Phase 3,Phase 2
13 Contraceptive Agents Phase 4,Phase 3,Phase 2
14 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2
15 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
16 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1
17 Norgestimate, ethinyl estradiol drug combination Phase 4,Phase 3,Phase 2
18 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2
19 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2
20 Fluoroquinolones Phase 4,Phase 3,Phase 2,Phase 1
21 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
23
Dipivefrin Approved Phase 3,Phase 2 52365-63-6 3105
24
Tobramycin Approved, Investigational Phase 3 32986-56-4 36294 5496
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
26
Bacitracin Approved, Vet_approved Phase 3 1405-87-4 10909430 439542
27
Zinc Approved, Investigational Phase 3 7440-66-6
28
Neomycin Approved, Vet_approved Phase 3 1404-04-2 8378
29
Ofloxacin Approved Phase 3,Phase 2 82419-36-1 4583
30
Levofloxacin Approved, Investigational Phase 3,Phase 2 100986-85-4 149096
31
Povidone Approved Phase 3 9003-39-8
32
Iodine Approved, Investigational Phase 3 7553-56-2 807
33
Povidone-iodine Approved Phase 3 25655-41-8
34
Azithromycin Approved Phase 3,Phase 1 83905-01-5 55185 447043
35
Pentetic acid Approved Phase 3 67-43-6
36
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
37
Edetic Acid Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
38
Calcium polycarbophil Approved Phase 3 126040-58-2
39
Vancomycin Approved Phase 3 1404-90-6 14969 441141
40
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
41 Pazufloxacin Investigational Phase 3,Phase 2 127045-41-4
42 Antineoplastic Agents, Hormonal Phase 3
43 Gastrointestinal Agents Phase 3
44
protease inhibitors Phase 3
45 Peripheral Nervous System Agents Phase 3
46 Autonomic Agents Phase 3
47 Antiemetics Phase 3
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
49 HIV Protease Inhibitors Phase 3
50 Anti-Inflammatory Agents Phase 3

Interventional clinical trials:

(show all 34)
# Name Status NCT ID Phase Drugs
1 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
2 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
3 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
4 Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis Unknown status NCT01227915 Phase 3 Tobracort;Tobradex
5 Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis Unknown status NCT01227863 Phase 3 MAXINOM®;Maxitrol®
6 A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. Completed NCT00347932 Phase 3 ISV-403;Vehicle
7 An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Completed NCT01573910 Phase 3 Moxifloxacin ophthalmic solution, 0.5%;Ofloxacin ophthalmic solution, 0.3%
8 Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo Completed NCT03004924 Phase 3 SHP640;PVP-I 0.6%;Placebo
9 Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis Completed NCT00565123 Phase 2, Phase 3 0.5% levofloxacin eye drops;0.5% levofloxacin eye drops
10 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00331916 Phase 3 quinolone
11 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00332293 Phase 3 Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
12 Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004) Completed NCT00105469 Phase 3 AzaSite;Tobramycin
13 Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) Completed NCT00105534 Phase 3 AzaSite
14 Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Completed NCT00972777 Phase 2, Phase 3 Besifloxacin;Vehicle (Placebo)
15 A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis Completed NCT00348348 Phase 3 Besifloxacin;Moxifloxacin solution
16 Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Completed NCT00759148 Phase 3 Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
17 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00509873 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
18 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00518089 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
19 Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. Completed NCT01155999 Phase 3 T1225;Tobramycin
20 Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis Completed NCT00357773 Phase 3 Azithromycin (T1225)
21 Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Completed NCT01175590 Phase 3 Besivance;Vehicle
22 Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis Completed NCT00732446 Phase 3 Moxifloxacin and Dexamethasone combined;Moxifloxacin;Dexamethasone
23 Prevention of Bacterial Infections in Newborn Completed NCT01800942 Phase 3 Azithromycin and Placebo
24 Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis Recruiting NCT02432807 Phase 3 Vancomycin 1.1%;Placebo
25 Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. Active, not recruiting NCT03696342 Phase 3 Pazufloxacin;Zymar
26 Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis Terminated NCT01740388 Phase 3 Besifloxacin;Vehicle
27 Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis Terminated NCT01330355 Phase 3 Besivance;Gatifloxacin
28 Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis Completed NCT00622908 Phase 2 ISV-403;Vehicle
29 Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis Completed NCT01877694 Phase 2 Auriclosene Solution 0.3%;Auriclosene Vehicle
30 Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) Completed NCT02980523 Phase 2 PRO-157;Vigamox;Zymar®;Lagricel Ofteno®
31 A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. Terminated NCT01928693 Phase 2 Besivance 0.6% Ophthalmic Suspension;Zymaxid 0.5% Ophthalmic Solution;Vigamox 0.5% Ophthalmic Solution
32 Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis Withdrawn NCT01238783 Phase 2 AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension;AL-15469A 0.5%;AL-6515 0.3%;Vehicle
33 Systemic Pharmacokinetics of BOL-303224-A Completed NCT00407589 Phase 1 BOL-303224-A
34 Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers Recruiting NCT03235141 Phase 1 azithromycin eye drops by essex;azithromycin eye drops

Search NIH Clinical Center for Bacterial Conjunctivitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: conjunctivitis, bacterial

Genetic Tests for Bacterial Conjunctivitis

Anatomical Context for Bacterial Conjunctivitis

MalaCards organs/tissues related to Bacterial Conjunctivitis:

41
Eye, Testes

Publications for Bacterial Conjunctivitis

Articles related to Bacterial Conjunctivitis:

(show top 50) (show all 165)
# Title Authors Year
1
Bacterial conjunctivitis in childhood: etiology, clinical manifestations, diagnosis, and management. ( 29380707 )
2018
2
Contact lenses with dual drug delivery for the treatment of bacterial conjunctivitis. ( 29960036 )
2018
3
Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis. ( 29847658 )
2018
4
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. ( 29624493 )
2018
5
Management of Bacterial Conjunctivitis in Children-Preferred Practice Pattern in Northern Greece. ( 30157160 )
2018
6
Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis. ( 30203775 )
2018
7
Topical Antibiotics for Clinical and Microbiological Cure of Bacterial Conjunctivitis. ( 30421517 )
2018
8
Epidemiology of bacterial conjunctivitis in chinchillas (Chinchilla lanigera): 49 cases (2005 to 2015). ( 28276116 )
2017
9
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates. ( 28078599 )
2017
10
Resistant Infantile Bacterial Conjunctivitis in Egypt: A Microbiology Study. ( 29131910 )
2017
11
Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment. ( 28708424 )
2017
12
Adult bacterial conjunctivitis: resistance patterns over 12 years in patients attending a large primary eye care centre in the UK. ( 29354693 )
2017
13
A chronological study of the bacterial pathogen changes in acute neonatal bacterial conjunctivitis in southern China. ( 28950852 )
2017
14
Patient demographic and microbiology trends in bacterial conjunctivitis in children. ( 29247795 )
2017
15
Neonatal Bacterial Conjunctivitis in Korea in the 21st Century. ( 28002109 )
2016
16
Acute bacterial conjunctivitis - antibiotic susceptibility and resistance to commercially available topical antibiotics in Nepal. ( 28242882 )
2016
17
A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness. ( 25945033 )
2015
18
Preparation and in vitro/in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis. ( 25886078 )
2015
19
Deep subconjunctival injection of gentamicin for the treatment of bacterial conjunctivitis in macaques (Macaca mulatta and Macaca fascicularis). ( 25693106 )
2015
20
Gatifloxacin 0.5% Administered Twice Daily for the Treatment of Acute Bacterial Conjunctivitis in Patients One Year of Age or Older. ( 25244402 )
2014
21
Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. ( 24526744 )
2014
22
The role of besifloxacin in the treatment of bacterial conjunctivitis. ( 24566460 )
2014
23
An evaluation of the reclassification of ophthalmic chloramphenicol for the management of acute bacterial conjunctivitis in community pharmacies in Western Australia. ( 24841453 )
2014
24
External ophthalmomyiasis caused by Oestrus ovis misdiagnosed as bacterial conjunctivitis. ( 23780871 )
2013
25
Epidemiological study of hospital-acquired bacterial conjunctivitis in a level III neonatal unit. ( 23766676 )
2013
26
A new diagnostic index for bacterial conjunctivitis in primary care. A re-derivation study. ( 24256320 )
2013
27
Identification of causative pathogens in eyes with bacterial conjunctivitis by bacterial cell count and microbiota analysis. ( 23246122 )
2013
28
A case of recalcitrant bacterial conjunctivitis. ( 24555257 )
2013
29
The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis. ( 24142473 )
2013
30
Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. ( 22420526 )
2012
31
Bacterial conjunctivitis. ( 22348418 )
2012
32
Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective. ( 23650458 )
2012
33
Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. ( 22729919 )
2012
34
Antibiotics versus placebo for acute bacterial conjunctivitis. ( 22972049 )
2012
35
Bacterial conjunctivitis: a review of therapies and approaches. ( 23189448 )
2012
36
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections. ( 23233796 )
2012
37
Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin. ( 22644963 )
2012
38
Bacterial conjunctivitis in children: antibacterial treatment options in an era of increasing drug resistance. ( 20724317 )
2011
39
Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis. ( 21175242 )
2011
40
Treatment of bacterial conjunctivitis in children. ( 21323206 )
2011
41
Bacterial conjunctivitis in children: a current review of pathogens and treatment. ( 21897142 )
2011
42
Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. ( 21681652 )
2011
43
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. ( 21397770 )
2011
44
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes. ( 22034555 )
2011
45
High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis. ( 21988450 )
2011
46
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. ( 22034556 )
2011
47
Bacterial conjunctivitis and of antibiotics in Dhulikhel Hospital-Kathmandu University Hospital. ( 22610873 )
2011
48
Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis. ( 23861618 )
2011
49
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis. ( 21573098 )
2011
50
The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis. ( 21604820 )
2011

Variations for Bacterial Conjunctivitis

Expression for Bacterial Conjunctivitis

Search GEO for disease gene expression data for Bacterial Conjunctivitis.

Pathways for Bacterial Conjunctivitis

GO Terms for Bacterial Conjunctivitis

Sources for Bacterial Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....